Les Sulewski
Stock Analyst at Oppenheimer
(4.13)
# 1,585
Out of 5,058 analysts
185
Total ratings
48.1%
Success rate
10.2%
Average return
Main Sectors:
Stocks Rated by Les Sulewski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterated: Buy | $50 | $22.09 | +126.35% | 22 | Oct 12, 2026 | |
| PCRX Pacira BioSciences | Downgraded: Hold | n/a | $36.31 | - | 26 | Oct 8, 2026 | |
| AMRX Amneal Pharmaceuticals | Initiated Coverage: Buy | $27 | $19.91 | +35.61% | 22 | Sep 23, 2026 | |
| ANIP ANI Pharmaceuticals | Initiated Coverage: Hold | $85 | $73.89 | +15.04% | 26 | Sep 23, 2026 | |
| EPA: MEDCL MedinCell S.A. | Initiated Coverage: Buy | €22.00 → €35.00 | €29.06 | +20.44% | 2 | Sep 23, 2026 | |
| TLV: TEVA Teva Pharmaceutical Industries Limited | Initiated Coverage: Buy | ILA 15,317 | ILA 12,000 | +27.64% | 1 | Sep 23, 2026 | |
| INVA Innoviva | Initiated Coverage: Buy | $35 | $21.21 | +65.02% | 1 | Sep 23, 2026 | |
| VNDA Vanda Pharmaceuticals | Initiated Coverage: Buy | $18 → $10 | $4.57 | +118.82% | 5 | Sep 23, 2026 | |
| VTRS Viatris | Initiated Coverage: Buy | $20 → $25 | $17.64 | +41.72% | 9 | Sep 23, 2026 | |
| CRMD CorMedix | Reiterated: Buy | n/a | $7.38 | - | 23 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.64 | - | 18 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 → $4 | $1.15 | +247.83% | 19 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $86.16 | n/a | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24.24 → $19.97 | $18.17 | n/a | 5 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.25 | n/a | 5 | Jul 9, 2024 |
Collegium Pharmaceutical
Oct 12, 2026
Reiterated: Buy
Price Target: $50
Current: $22.09
Upside: +126.35%
Pacira BioSciences
Oct 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $36.31
Upside: -
Amneal Pharmaceuticals
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $27
Current: $19.91
Upside: +35.61%
ANI Pharmaceuticals
Sep 23, 2026
Initiated Coverage: Hold
Price Target: $85
Current: $73.89
Upside: +15.04%
MedinCell S.A.
Sep 23, 2026
Initiated Coverage: Buy
Price Target: €22.00 → €35.00
Current: €29.06
Upside: +20.44%
Teva Pharmaceutical Industries Limited
Sep 23, 2026
Initiated Coverage: Buy
Price Target: ILA 15,317
Current: ILA 12,000
Upside: +27.64%
Innoviva
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $21.21
Upside: +65.02%
Vanda Pharmaceuticals
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $18 → $10
Current: $4.57
Upside: +118.82%
Viatris
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $17.64
Upside: +41.72%
CorMedix
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.38
Upside: -
May 1, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.64
Upside: -
Apr 16, 2026
Reiterated: Buy
Price Target: $5 → $4
Current: $1.15
Upside: +247.83%
Aug 8, 2024
Reiterated: Buy
Price Target: n/a
Current: $86.16
Upside: n/a
Jul 26, 2024
Reiterated: Buy
Price Target: $24.24 → $19.97
Current: $18.17
Upside: n/a
Jul 9, 2024
Rated: Hold
Price Target: n/a
Current: $2.25
Upside: n/a